Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Wednesday, H.C. Wainwright reaffirmed a Buy rating and a price target of $54.00 on Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) shares. The clinical-stage biopharmaceutical company, currently valued at $3.2 billion, maintains a strong liquidity position with a current ratio of 3.49, though InvestingPro data indicates the company is quickly burning through cash. According to InvestingPro’s Fair Value model, the stock appears slightly undervalued at current levels. The positive stance comes after Biohaven’s small molecule IgG degrader, BHV-1300, showed promising results in a Phase 1 study. BHV-1300 is designed to target FcRn inhibition and demonstrated an 84% reduction of total IgG, with a median reduction of 80% after weekly subcutaneous doses of 1000mg. These reductions were achieved rapidly following each dose and were sustained over the four-week study period. The market has shown significant volatility in response to these developments, with InvestingPro reporting a 15.6% decline in share price over the past week.
The encouraging results of BHV-1300 follow Biohaven’s previous announcement last year, which reported dose-dependent IgG reductions ranging from 5% to 37%, and greater than 60% reductions in targeted IgG at the lowest subcutaneous dose tested in the MAD study. The company had initially indicated the potential for up to 90% IgG reduction, but expectations were adjusted based on initial data. The current 84% reduction is considered strong and competitive, particularly in comparison with similar treatments from companies like argenx and Immunovant (NASDAQ:IMVT).
Biohaven’s BHV-1300 has been designed to selectively spare IgG3, which is the most efficient at activating complement. This specificity may have influenced the company’s pivot from focusing on myasthenia gravis to Graves’ Disease, where complement activation is less critical. This strategic shift puts Biohaven in direct competition with Immunovant, which has already begun a pivotal study for Graves’ Disease.
The Phase 1 study of BHV-1300 also reported no clinically significant increases in liver enzymes such as ALT/AST, bilirubin, or cholesterol, nor were there significant decreases in albumin over the four-week period. Additionally, no clinically significant effects were observed in other immunoglobulins, including IgG3, IgA, IgGE, or IgM compared to baseline. These safety findings support the continuation of the clinical development of BHV-1300. With analyst targets ranging from $54 to $77 and an EBITDA of -$866.36M, investors seeking deeper insights can access comprehensive analysis and 12 additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Biohaven Pharmaceutical Holding has been the subject of various analyst reports following its latest earnings and program updates. Jefferies adjusted its price target for Biohaven, lowering it from $64 to $63, but maintained a Buy rating, citing the promising data from BHV-1300, despite some concerns about dosage levels. TD Cowen also reaffirmed a Buy rating with a $75 price target, highlighting the significant progress of the BHV-1300 program, which showed an 80-84% reduction in immunoglobulin G (IgG) levels. RBC Capital Markets maintained an Outperform rating with a $61 target, emphasizing the potential of Biohaven’s pipeline despite setbacks in its bipolar treatment trials.
Bernstein adjusted its price target from $73 to $57, retaining an Outperform rating, following mixed results from Biohaven’s degrader Phase 1 study and concerns about cash needs. Piper Sandler reiterated an Overweight rating with a $76 target, focusing on the positive data for BHV-1300 and upcoming trials for Graves’ disease. The analyst reports reflect a mixed but generally optimistic outlook on Biohaven’s future, with continued interest in its drug development pipeline and potential for significant advancements in treating various disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.